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The P2X7 Receptor-Interleukin-1
Liaison
Anna Lisa Giuliani, Alba C. Sarti, Simonetta Falzoni and Francesco Di Virgilio*
Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy
Interleukin-1β (IL-1β) plays a central role in stimulation of innate immune system and
inflammation and in several chronic inflammatory diseases. These include rare hereditary
conditions, e.g., auto-inflammatory syndromes, as well as common pathologies, such
as type II diabetes, gout and atherosclerosis. A better understanding of IL-1β synthesis
and release is particularly relevant for the design of novel anti-inflammatory drugs.
One of the molecules mainly involved in IL-1β maturation is the P2X7 receptor
(P2X7R), an ATP-gated ion channel that chiefly acts through the recruitment of the
NLRP3 inflammasome-caspase-1 complex. In this review, we will summarize evidence
supporting the key role of the P2X7R in IL-1β production, with special emphasis on
the mechanism of release, a process that is still a matter of controversy. Four different
models have been proposed: (i) exocytosis via secretory lysosomes, (ii) microvesicles
shedding from plasma membrane, (iii) release of exosomes, and (iv) passive efflux across
a leaky plasma membrane during pyroptotic cell death. All these models involve the
P2X7R.
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THE INFLAMMATORY PROCESS
Inflammation has been the object of countless studies and experimental observations since
its definition more than 2000 years ago (Celso, De Medicina, 47 CE). Nevertheless, many
aspects of this process are not fully understood, and therefore inflammation is still nowadays
a field of extensive investigation, especially in view of its crucial role in the pathogenesis of
many acute and chronic diseases. Accordingly, inflammation is a fertile ground of research for
the development of novel drugs. Diverse chemical mediators with pro- or anti-inflammatory
activity have been identified over the years. These range from histamine to bioactive lipids, e.g.,
prostaglandins and leukotriens, from free radicals, e.g., reactive oxygen species (ROS) and nitric
oxide (NO), to cytokines, e.g., interleukins (ILs) and tumour necrosis factor (TNF). Among all
these mediators, interleukin-1β (IL-1β) is recognized as one of the earliest and most potent
pro-inflammatory agents synthesized and released in response to infectious agents and injuries,
and therefore central to both septic and sterile inflammation (Gabay et al., 2010; Dinarello,
2011).
AN OVERVIEW ON INTERLEUKIN-1 (IL-1)
The term Interleukin-1 (IL-1), also known as leukocyte endogenous mediator, hematopoietin 1,
endogenous pyrogen, catabolin and osteoclast activating factor, was used in the past to indicate a
factor mediating many different pro-inflammatory and catabolic effects.
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The history of IL-1 begins with studies on the endogenous
factor produced by activated leukocytes that causes fever. As such,
IL-1 was originally described in Menkin (1943), who reported the
isolation of a pyrogenic euglobulin from inflammatory exudate
named “pyrexin” or “endogenous pyrogen.”
These initial studies were followed by the groundbreaking
contributions of Beeson (1948) who confirmed Menkin’s
observation and further reported that an endotoxin-free,
protein-containing material, released from rabbit peritoneal
leukocytes, caused the rapid onset of fever after injection
into rabbits. This was the first time in which the mechanism
behind fever, in the absence of infection, was described. After
Beeson’s paper, there was a surge of studies on the links
between infection/inflammation and fever, that culminated in the
demonstration by Bodel and Atkins (1967) that human blood
monocytes produced a pyrogen, similar to that released by rabbit
neutrophils, by de novo synthesis.
Gery and Waksman (1972) described the effect on lymphocyte
proliferation of soluble factors released in response to antigenic
or mitogenic stimuli, and a few years later Dinarello and
Bernheim (1981) purified the human leukocytic pyrogen from
peripheral blood mononuclear cells (PBMCs) in vitro stimulated
with heat-killed Staphylococcus epidermidis. Leukocytic pyrogen
was also shown to enhance T cells responses to antigens and to
promote synthesis of acute phase proteins (Kampschmidt et al.,
1973).
Initially, the vast number of biological activities attached to
a single molecule generated some confusion in the scientific
community, however, with the cloning of IL-1 by Lomedico
et al. (1984), the use of recombinant IL-1 established that IL-1
was indeed a pleiotropic cytokine mediating a great variety of
inflammatory, as well as immunological, responses. Thanks to the
seminal work of Dinarello, we now know that IL-1 is the founding
member of a family of cytokines.
The IL-1 cytokine family consists of 11 members with
different roles in inflammation. Seven of them, i.e., IL-1α, IL-1β,
IL-18, IL-33, IL-36α, IL-36β and IL-36γ, own well-demonstrated
pro-inflammatory properties, whereas four members, IL-1Ra,
IL-36Ra, IL-37 and IL-38, are anti-inflammatory (Garlanda et al.,
2013; Borthwick, 2016). Cytokines of the IL-1 family ligate and
activate specific plasma membrane receptors, the IL-1 receptor
family, comprised of 10 members, named IL-1R1, IL-1R2, IL-1R3
(IL-1RAcP), IL-R4 (ST2), IL-1R5 (IL-18Rα), IL-1R6 (IL-R36),
IL-1R7 (IL-18Rβ), IL-1R8 (SIGIRR: single Ig IL-1R-related
molecule or TIR8: three Ig domain-containing IL-1R related),
IL-1R9 (IL-33R), IL-1R10 (TIGIRR-1) (Garlanda et al., 2013).
Interleukin-1β (IL-1β), a crucial factor of host defense in
response to infections and injuries, is the best characterized and
most extensively studied member of the IL-1 family (Dinarello,
1996). In the last decade, IL-1β has also emerged as a causative
agent and a therapeutic target for an expanding number
of systemic and local inflammatory conditions named “auto-
inflammatory diseases.” The auto-inflammatory diseases include
rare hereditary conditions as well as common pathologies.
Recently, increasing evidence shows that the same pathogenetic
mechanisms responsible for the activation of innate immunity
in inherited auto-inflammatory diseases may also play a key
role in sustaining inflammation in several frequent multifactorial
pathologies, such as type II diabetes, gout, pseudogout, and
atherosclerosis (Ginaldi et al., 2005).
Il-1β, usually not expressed by healthy resting cells, is
mainly produced by activated inflammatory cells of the myeloid
lineage. Production of IL-1β is a multistep process involving
synthesis of immature pro-IL-1β, proteolytic cleavage to mature
IL-β and, finally, release into the extracellular environment.
Synthesis of the immature full-length pro-IL-1β is started with
the recognition via Toll-like receptors (TLRs) of molecules
derived from invading micro-organisms [pathogen-associated
molecular patterns (PAMPs)] (Janeway, 2001). Once synthesized,
the 31 kD pro-IL-1β undergoes a proteolytic cleavage catalyzed
by caspase-1 (casp-1) which removes 116 N-terminal aminoacids
to generate the 17 kD bioactive form, now ready to be secreted.
If conversion to the 17 kD form does not occur, pro-IL-1β
is polyubiquitinated and targeted for proteasomal degradation
(Ainscough et al., 2014). Activation of casp-1, in turn, depends
on assembly and activation of inflammasomes, multisubunit
organelles that convert pro-casp-1 to active casp-1 (Thornberry
et al., 1992; Martinon et al., 2002; Ogura et al., 2006).
The NLRP3 inflammasome has been investigated in depth
and recognized as a very, likely the most, efficient machinery
for pro-IL-1β maturation, and the biology of this cytokine has
been intimately intertwined with that of the inflammasomes
and of inflammasome-activating agents (Martinon et al., 2002;
Di Virgilio, 2013). Inflammasomes are high molecular weight
protein complexes assembled in the cytosolic compartment
in response to a variety of stimuli, either of exogenous
(PAMPs) or endogenous [danger/damage associated molecular
patterns (DAMPs)] origin. PAMPs include bacteria- as well
as virus derived components, whereas DAMPs encompass
different classes of molecules normally segregated inside the
cells (Venereau et al., 2015). DAMPs are released in response
to invasion by micro-organisms (septic inflammation) as wells
as to physical, chemical, metabolic non-infectious agents (sterile
inflammation) (Gallucci et al., 1999). DAMPs released in the
extracellular milieu fulfill the task of alerting surrounding cells,
especially of immune lineages, of an incumbent danger or a
damage (Venereau et al., 2015; Nie et al., 2016). Among DAMPs,
extracellular ATP and other nucleotides play an undisputed role.
Nucleotide signaling is central in IL-1β maturation and
release, as well as in other immune responses, such as
neutrophil and macrophage chemotaxis, intracellular microbe
killing, NADPH-oxidase activation, T lymphocyte proliferation
and differentiation (Di Virgilio, 1995; Bours et al., 2006; Ferrari
et al., 2006; Junger, 2011; Eltzschig et al., 2012; Idzko et al.,
2014; Cekic and Linden, 2016). Extracellular ATP acts at plasma
membrane purinergic P2 receptors, chiefly the P2X7 receptor
(P2X7R) subtype, to drive NLRP3 inflammasome activation and
IL-1β processing and release (Ferrari et al., 1997). ATP is released
into extracellular environment during inflammation, ischemia,
hypoxia, or other harmful events, via lytic (e.g., cell necrosis)
or non-lytic (e.g., exocytosis, plasma membrane channels or
pores) pathways. Pathways for non-lytic ATP release include
pannexins (Dahl, 2015), connexins (Evans et al., 2006), ABC
transporters (Cantiello, 2001), secretory vesicles (Sneddon and
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Westfall, 1984; Wang et al., 2013), and the P2X7R (Pellegatti et al.,
2005; Suadicani et al., 2006).
THE P2X7R
Several reports underscore the pivotal role of ATP-mediated
P2X7R activation in IL-1β release from activated immune cells
(monocytes, macrophages, and microglia) (Di Virgilio et al.,
1998; Pelegrin et al., 2008; Sanz et al., 2009). Macrophages
from genetically modified mice lacking the P2X7R, ASC or
NLRP3, do not release IL-1β in response to ATP (Solle et al.,
2001; Mariathasan et al., 2004, 2006). Moreover, oxidized ATP,
an irreversible blocker of the P2X7R (Murgia et al., 1993)
abrogates ATP-induced IL-1β release from immune cells (Ferrari
et al., 1997). P2X7R stimulation also induces fast release into
the cytosol of oxidized mitochondrial DNA (mitoDNA) that
promotes NLRP3 inflammasome assembly by direct interaction
(Nakahira et al., 2011; Shimada et al., 2012).
The P2X7R is a bi-functional ATP-gated plasma membrane
ion channel that upon sustained stimulation undergoes a
transition that generates a non-selective pore permeable to
aqueous solutes of MW up to 900 Da (Di Virgilio, 2000).
The P2X7R is widely distributed in human tissues, the highest
expression being in cells of the immune and inflammatory
systems, especially of the myeloid lineage (Di Virgilio, 1995, 2015;
Karmakar et al., 2016). The P2X7R is the seventh, and latest
to be cloned, member of the P2X receptor (P2XR) subfamily
activated by an agonist concentration about 100 fold higher
than the other members of the family. P2XRs are ATP-gated
channels permeable to monovalent (Na+, K+) and divalent
(Ca2+) cations formed by the assembly of the same (homo) or
different (hetero) P2X subunits. Six homomeric (P2X1R-P2X5R
and P2X7R) and six heteromeric (P2X1/2R, P2X1/4R, P2X1/5R,
P2X2/3R, P2X2/6R, and P2X4/6R) functional P2XRs have been
described so far (Dubyak, 2007; North, 2016). Among P2X
subunits, the P2X7 is generally thought not to assemble with
the others, and thus forming P2X7 only homomeric channels.
High sequence homology of P2X7R with the P2X4R (41%
identity, 71% similarity), suggests a common origin by gene
duplication. Therefore, the solved crystal structure for zebrafish
P2X4R (Kawate et al., 2009; Hattori and Gouaux, 2012) has
been used to model the 3D conformation of the P2X7R (Jiang
et al., 2013). Useful insights as to ATP binding pocket, ion
permeation pathway, site of antagonist binding and interaction
with allosteric modulators are also derived from the crystal
structure of the panda P2X7R (Karasawa and Kawate, 2016).
Further information are ensued by recent 3D resolution of the
human P2X3R (Mansoor et al., 2016).
The P2X subunits are characterized by a large extracellular
loop, which includes agonist- and antagonist-binding sites,
two short transmembrane domains, and intracellular N- and
C-termini. The P2X7R with an extended C-terminal tail of 239 aa
and an overall length of 595 aa, is the largest in the P2XR family.
Transmembrane domains are responsible for the interactions
among subunits and the formation of the ion-permeation
pathway (Hattori and Gouaux, 2012; Grimes and Young, 2015).
The intracellular C-tail interacts with different intracellular
molecules such as heat shock proteins (HSP), cytoskeletal
components, kinases and possibly also with membrane proteins.
Among these latter, pannexin-1 and connexin-43 hemichannels
have been variably implicated in the formation of the P2X7R-
associated large-conductance pore and therefore in P2X7R-
dependent IL-1β secretion, and in the release of extracellular
ATP (Pelegrin and Surprenant, 2007; Baroja-Mazo et al., 2013).
P2X7R has also been found to interact directly with components
of inflammasomes, such as NLRP2, ASC (apoptosis-associated
speck-like protein containing a CARD) and NLRP3 (Minkiewicz
et al., 2013; Franceschini et al., 2015; Salaro et al., 2016). P2X7R
activation by ATP is one of the most potent stimuli for NLRP3
inflammasome activation (Mariathasan et al., 2006; Munoz-
Planillo et al., 2013).
THE NLRP3 INFLAMMASOME
Inflammasomes are cellular organelles with a fundamental role
in inflammation and cell death (Martinon et al., 2002; Guo
et al., 2015; Rathinam and Fitzgerald, 2016). The basic scaffold
subunit is a nucleotide-binding and oligomerization domain
(NOD)-like receptor (NLR) that contains a C-terminal leucine-
rich repeat (LRR) domain, a central NACHT nucleotide-binding
domain (NOD) and an N-terminal pyrin domain (a CARD
domain in the NLRC4 inflammasome). The pyrin domain of
the NLR scaffold subunit interacts with the pyrin domain of
an adaptor molecule named ASC. NLR-driven ASC recruitment
drives pro-casp-1 activation via CARD domains present on
both ASC and pro-casp-1, thus resulting in pro-casp-1 cleavage
and casp-1 activation. Casp-1 then cleaves pro-IL-1β and pro-
IL-18 to produce the mature forms of both cytokines (Benko
et al., 2008; Schroder and Tschopp, 2010; Broz and Dixit, 2016;
Prochnicki et al., 2016). Inflammasomes play a cardinal role
in innate immunity thanks to their ability to sense PAMPs
and DAMPs (He et al., 2016a; Kim et al., 2016). Within
the subfamily of NLRP inflammasomes (i.e., inflammasomes
based on NLR scaffold molecules with an N-terminal pyrin
domain) NLRP3 is currently enjoying the widest popularity
as crucial sensor for a large number of danger signals and
as the main platform for IL-1β processing. Activating stimuli
for the NLRP3 inflammasome include bacterial toxins, flagellin,
muramyl dipeptide, viral nucleic acids and fungal products, as
well as endogenous components such as ATP, cholesterol crystals,
monosodium urate, glucose and amyloid β, environmental
pollutants, such as silica, asbestos or physical agents such as UV
radiations (Kim et al., 2016).
The identity of the activating stimulus of the NLRP3
inflammasome has been a hot issue ever since its discovery.
Nowadays there is basically general consensus on the key role
played by K+ eﬄux, which seems to be the final common
pathway for many different agents (Munoz-Planillo et al., 2013).
Most efficient NLRP3 activators include extracellular ATP, K+
ionophores, and several extracellular crystals, all known to
decrease the cytosolic K+ level. The mechanism whereby these
different agents lower K+ is not entirely clear, but many converge
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on P2X7R activation (Alves et al., 2014; Prochnicki et al.,
2016). In fact, while P2X7R opening or nigericin, a carboxylic
K+ ionophore, directly allow K+ eﬄux along its concentration
gradient, the mechanism by which crystals, such as monosodium
urate, deplete intracellular K+ is obscure. To support the
contribution of K+ depletion, drugs inhibiting the Na+/K+-
ATPase also trigger NLRP3 inflammasome activation (Walev
et al., 1995; Munoz-Planillo et al., 2013). Albeit inhibition of
Na+/K+-ATPase also causes plasma membrane depolarization,
there is no evidence that depolarization itself may trigger P2X7R
pore opening and/or IL-1β release (Di Virgilio, 2013). The central
role of intracellular K+ is further supported by the finding that
a K+ drop is also necessary to allow recruitment of the Nima-
related kinase (NEK)7 protein to the NLRP3 inflammasome (He
et al., 2016b). On the other hand, the mechanism by which the
drop in the K+ concentration drives NEK7 recruitment, NLRP3
inflammasome assembly and activation is utterly unknown.
The NLRP3 inflammasome can be also activated by a non-
canonical pathway involving casp-11. Casp-11, and its human
orthologs casp-4 and -5, function as cytosolic LPS sensors (Shi
et al., 2014). Once activated by LPS, casp-11 induces cleavage
of the plasma membrane channel pannexin-1 (Yang et al., 2015)
producing two events consisting of K+ eﬄux, that activates
NLRP3, and release of ATP that acts as a P2X7R agonist
to promote further NLRP3 activation and cell death (Yang
et al., 2015). The casp-11/pannexin-1/NLRP3 inflammasome axis
is proposed to promote IL-1β/IL-18 production (Yang et al.,
2015). In addition, active casp-11 triggers pyroptosis via cleavage
of Gasdermin D (GSDMD) leading to accumulation of free
active N-terminal domains of this protein which disrupt cellular
functions by forming plasma membrane pores (He et al., 2015;
Vince and Silke, 2016). Casp-11-mediated cell death, like casp-1-
induced pyroptosis, requires cleavage of the GSDMD pyroptotic
factor (He et al., 2015; Kayagaki et al., 2015; Shi et al., 2015). Casp-
11 mediated cell death is indeed abrogated in GSDMD deficient
cells and, although it is not clear if GSDMD is the terminal
pyroptotic factor, its N-terminal domain released following casp-
11-dependent cleavage is sufficient to cause pyroptosis (Kayagaki
et al., 2015; Shi et al., 2015). It has been proposed that, since
casp-1 is required for both pyroptosis and IL-1β cleavage, IL-
1β is passively released alongside DAMPs following plasma
membrane rupture (Vince and Silke, 2016). The finding that in
macrophages lack of GSDMD has no effect on NLRP3-stimulated
IL-1β processing by casp-1 but prevents IL-1β secretion (He et al.,
2015; Shi et al., 2015), suggests that casp-1 is necessary for IL-1β
cleavage whereas GSDMD is indispensable for its release. Recent
findings have revealed that in human monocytes stimulated with
LPS casp-4 and -5 act as key determinants in one-step non-
canonical NLRP3 inflammasome activation culminating with
IL-1β release (Vigano et al., 2015). This one-step pathway has
been suggested to require Syk activity and Ca2+ influx due
to CD14/TLR4-mediated LPS internalization (Vigano et al.,
2015). NLRP3 activation and IL-1β release can also be driven
by K+ independent mechanisms involving ROS generation
or RIPK1/FADD/casp-8 recruitment (Zhou et al., 2011; Heid
et al., 2013; He et al., 2016a; Sanman et al., 2016). Converging
experimental findings seem to rule out a role for cytosolic Ca2+
increases (Brough et al., 2003; Rada et al., 2014; Katsnelson
et al., 2015). In some non-immune cells, e.g., astrocytes, IL-
1β maturation has been reported to be due to P2X7-dependent
NLRP2 stimulation via a process involving direct NLRP2, P2X7R,
pannexin-1 interaction (Minkiewicz et al., 2013). Finally, IL-1β
can also be processed independently of inflammasome/casp-1
activation, as shown in casp-1 deficient mice, where pro-IL-
1β to IL-1β extracellular conversion is catalyzed by various
neutrophil proteases such as elastase, proteinase-3, granzyme A
and cathepsine G (Fantuzzi et al., 1997; Joosten et al., 2009).
P2X7R stimulation by itself has no or little effect on pro-
IL-1β cytoplasmic accumulation, therefore cells need priming
by agents that promote IL-1β gene transcription, which mainly
occur via NFκB activation. Typical priming agents are bacterial
lipopolysaccharide, zymosan and poly(I:C) (Ferrari et al., 1996;
Facci et al., 2014).
IL-1β RELEASE
The canonical pathway for the export of cellular proteins into the
extracellular space involves the ER and the Golgi apparatus that
together form the endo-membrane system through which the
vast majority of proteins are either targeted to the extracellular
space or to specialized sub-cellular compartments. At variance
with other cytokines, IL-1β lacks the conventional leader/signal
peptide and therefore is not targeted to the conventional ER-
Golgi secretory pathway (Rubartelli et al., 1990). This leads to
IL-1β accumulation into the cytosol after translation on free
ribosomes. Moreover, conversion of pro-IL-1 β to the mature
form by inflammasomes also takes place in the cytosol. Therefore,
release of mature IL-1 β requires non-classical mechanisms
of export from the cytosolic compartment (Rubartelli et al.,
1990; Wewers, 2004; Eder, 2009). A number of different
possible mechanisms have been proposed (Dubyak, 2012) and
summarized in Figure 1. They include exocytosis via secretory
lysosomes (Andrei et al., 1999; Andrei et al., 2004), microvesicle
shedding from plasma membrane (MacKenzie et al., 2001; Bianco
et al., 2005; Pizzirani et al., 2007), release of exosomes (Qu et al.,
2007), and, lastly, passive eﬄux across a leaky plasma membrane
during pyroptotic cell death (Bergsbaken et al., 2009; Martin-
Sanchez et al., 2016). The P2X7R has been implicated in all these
processes.
EXOCYTOSIS OF IL-1β-CONTAINING
SECRETORY LYSOSOMES
Rubartelli et al. (1990) presented the first evidence for a non-
classical secretory pathway for IL-1β release. Blockade of protein
transport and secretion through the ER-Golgi complex did
not affect IL-1β release, thus pointing to the involvement of
secretory lysosomes. Secretory lysosomes are unusual organelles
found principally in hematopoietic cells with a dual-function,
degradative and secretory (Blott and Griffiths, 2002). The
exocytic process can be triggered by different stimuli among
which ATP, possibly via the increase in the intracellular Ca2+
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FIGURE 1 | Pathways for IL-1β release from activated immune cells. IL-1β maturation is catalyzed by ATP-mediated stimulation of the P2X7R that drives
NLRP3 inflammasome assembly and casp-1 recruitment. Four models have been proposed for IL-1β release: (1) exocytosis of secretory lysosomes; (2) shedding of
plasma membrane-derived microvesicles; (3) exocytosis of multivesicular body (MVB)-derived exosomes; (4) passive efflux across hyperpermeable plasma
membrane during pyroptotic cell death.
concentration. Migration of exocytic lysosomes to the plasma
membrane is a microtubule-dependent process that brings the
lysosomes close to the plasma membrane allowing fusion and
release of their content into the extracellular space. This model
for IL-1β secretion is mainly based on morphological evidence
from ATP-stimulated monocytes where IL-1β was found to be
trapped within organelles akin to late endosomes and early
lysosomes (Andrei et al., 1999). In human monocytes and
mouse macrophages, ATP-stimulated, P2X7R-dependent release
of mature IL-1β and casp-1 strongly correlated with secretion of
the lysosomal markers cathepsin B, cathepsin D and lysosomal-
associated membrane protein 1 (LAMP1) (Andrei et al., 1999;
Carta et al., 2006). Both IL-1β and casp-1 are found in the
extracellular medium 20 min after ATP stimulation, suggesting
a similar time course. According to Rubartelli and coworkers
a fraction of intracellular pro-IL-1β is co-stored together with
pro-casp-1 within the secretory lysosomes, ready to be secreted
in response to P2X7R stimulation (Rubartelli et al., 1990).
The triggering stimulus is thought to be the P2X7R-induced
loss of intracellular K+, which activates a phosphatidylcholine-
specific phospholipase C, which in turn causes an increase in
cytosolic Ca2+, Ca2+-dependent phospholipase A2 activation
and finally exocytosis of the IL-1β-containing lysosomes.
These events are blocked by inhibitors of phospholipase A2
or phosphatidylcholine-specific phospholipase C. This model
suggests that, whereas the massive K+ eﬄux due to P2X7R
activation has a key role in the maturation of pro-IL-1β, the
intracellular Ca2+ increase is more directly responsible for IL-1β
secretion.
SHEDDING OF IL-1β-CONTAINING
PLASMA MEMBRANE MICROVESICLES
Surprenant and coworkers proposed a different vesicular
mechanism for IL-1β release from THP-1 monocytes
(MacKenzie et al., 2001). According to this mechanism,
P2X7R stimulation induces mature IL-1β accumulation at
discrete sub-plasmalemmal sites, where from it is then trapped
into small plasma membrane blebs that are finally rapidly
shed as microvesicles into the extracellular space (Figure 2).
Microvesicle shedding is preceded by flip of phosphatidylserine
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FIGURE 2 | Molecular mechanism for P2X7R-dependent microvesicle shedding. P2X7R activation promotes interaction of the C-terminal domain with a
src-protein tyrosine kinase (Srk-K), which in turn phosphorylates P38 MAP kinase (P38 MAPK). P38 MAPK induces flip of acidic sphingomyelinase (A-SMase) from
the inner to the outer plasma membrane leaflet. On the outer plasma membrane leaflet, A-SMase hydrolyzes sphingomyelin to generate ceramide that in turn alters
membrane fluidity, drives formation of plasma membrane blebs and promotes shedding of IL-1β-containing microvesicles (modified from Bianco et al., 2009).
(PS) to the outer leaflet of the plasma membrane. Microvesicles
size ranges from 200 nm to 1 µm, which makes them distinct
from the much larger apoptotic bodies derived from apoptotic
cells (1–4 µm size), and the smaller exosomes derived from
intraluminal vesicles of endosomal multivesicular bodies
(MVBs). A similar mechanism for IL-1β release has also been
observed in human monocyte-derived dendritic cells (DCs) and
mouse microglia (Bianco et al., 2005; Pizzirani et al., 2007). Shed
microvesicles contain (a) plasma membrane phospholipids, e.g.,
PS (MacKenzie et al., 2001), (b) membrane intrinsic proteins,
such as P2X7R, CD63, CD39, MHC-II, LAMP1 (Andrei et al.,
1999; Pizzirani et al., 2007) and (c) cytoplasmic proteins, such
as pro-IL-1β, pro-casp-1, IL-1β, casp-1, casp-3 and cathepsin D
(Gudipaty et al., 2003; Andrei et al., 2004; Bianco et al., 2005;
Carta et al., 2006; Pizzirani et al., 2007; Qu et al., 2007). It is not
clear how and if IL-1β finally eﬄuxes out of the microvesicles,
thus fulfilling its role as an extracellular signaling molecule, or
alternatively is delivered intracellularly following microvesicle
fusion with the plasma membrane of target cells. Verderio and
coworkers provided ample evidence showing that microvesicles
released from P2X7R-stimulated microglia fuse with the plasma
membrane of target cells (e.g., neurons), deliver their content
and affect target cell responses (e.g., synaptic activity) (Antonucci
et al., 2012; Turola et al., 2012; Verderio et al., 2012). We reported
some time ago that microvesicles shed from P2X7R-stimulated
DCs express the P2X7R and are lysed by exposure to extracellular
ATP, thus releasing their cargo of IL-1β (Pizzirani et al., 2007).
This observation led us to propose that IL-1β is released in the
vicinity of the target cell plasma membrane by ATP-stimulated
and P2X7R-dependent microvesicle rupture (Pizzirani et al.,
2007). In fact, it is known that due to continuous ATP release
into the extracellular space, cells are surrounded by an “ATP
halo” that generates an ATP concentration higher in the vicinity
of the plasma membrane than in the bulk solution. Thanks to
this ATP gradient, microvesicle journey across the interstitial
space should be relatively safe until they reach the target cell
surface where they are supposed to find an ATP concentration
sufficient to activate the P2X7R and trigger lysis.
EXOCYTOSIS OF IL-1β-CONTAINING
EXOSOMES
In mouse bone marrow-derived macrophages (BMDMs) the
main mechanism for non-classical IL-1β release has been
reported to be neither secretory lysosomes nor microvesicle
shedding, but rather P2X7R-stimulated MVBs formation and
exosome release (Qu et al., 2007). Exosomes are small vesicles
(30–100 nm) released upon fusion of MVBs with the cell plasma
membrane. Exosomes originate as intraluminal vesicles during
the process of MVBs formation. MVBs or late endosomes are
components of the endocytic pathway that range from 250 to
1000 nm in diameter. MVBs can either be degraded or fuse with
the plasma membrane, releasing the intraluminal vesicles into
the extracellular space. Intraluminal vesicles are then referred
to as exosomes following their extracellular release. During the
process of formation, transmembrane and peripheral membrane
proteins are incorporated into the exosome membrane, while
cytosolic components are enclosed within the vesicles. Exosomes
released from macrophages, DCs or B-lymphocytes contain
Frontiers in Pharmacology | www.frontiersin.org 6 March 2017 | Volume 8 | Article 123
fphar-08-00123 March 16, 2017 Time: 11:56 # 7
Giuliani et al. P2X7 and IL-1
soluble proteins present in the cytosol, such as pro-IL-1β, pro-
casp-1 and the respective mature form IL-1β and casp-1, and
plasma membrane proteins such as MHCI and MHCII, a feature
of exosomes derived from antigen presenting cells. From P2X7R-
stimulated BMDMs two distinct types of membrane-bound
vesicles are shed: (a) plasma membrane-derived microvesicles
carrying P2X7R and LAMP1, and (b) MVB-derived exosomes
lacking both P2X7R and LAMP1. However, both types of
vesicles are able to present peptide-MHCII complexes to T
cells (Ramachandra et al., 2010). Secretion of IL-1β and MHCII
are strongly inhibited in mice deleted of ASC and NLRP3,
suggesting the possibility that inflammasome complex regulate
the formation of MVBs and the accumulation of IL-1β and
casp-1, although the mechanism remains unclear (Qu et al.,
2009).
IL-1β RELEASE AS A CONSEQUENCE OF
PLASMA MEMBRANE DAMAGE AND
CELL DEATH
A model for IL-1β release involving plasma membrane damage
and cell death (whether by necrosis or apoptosis) has been
proposed several years ago (Hauser et al., 1986; Hogquist et al.,
1991). A major obstacle for the acceptance of this model
is the need for proteolytical activation of pro-IL-1β, which
is assumed to occur coordinately with its secretion, and the
consistent observation that cytoplasmic mature IL-1β levels are
very low (Perregaux et al., 1992). Of course, it is possible
that extracellular proteases, e.g., trypsin or cathepsins might
do the job, but in vivo relevance of extracellular pro-IL-1β
maturation is dubious. However, in a recent paper, Pelegrin
and co-workers have re-visited the cell permeabilization/cell
death model for IL-1β release from BMDMs taking advantage
of novel, highly sensitive, fluorescence-based technique to
measure IL-1β secretion and of a novel inhibitor, punicalagin
(Martin-Sanchez et al., 2016). Rigorous analysis of release of
the cytoplasmic marker lactic dehydrogenase and of IL-1β
revealed that the kinetics of two processes were closely over-
imposed. Furthermore, punicalagin, a polyphenolic compound
that efficiently prevents plasma membrane permeabilization in
response to a number of membrane-perturbing agents, fully
abolished ATP-dependent IL-1β secretion but not its processing,
thus showing that pro-IL-1β cleavage and mature IL-1β secretion
can be dissociated, and that a “leaky membrane” is needed for
IL-1β release. Since casp-1 activation is also a major driver of
pyroptotic cell death, Pelegrin and co-workers suggested that in
macrophages IL-1β secretion occurs via a non-specific increase in
plasma membrane permeability associated to cell death (Martin-
Sanchez et al., 2016).
IS THE P2X7R-TARGETING A
THERAPEUTICALLY LIVE OPTION?
Several studies show that P2X7R blockade efficiently antagonize
IL-1β release in different disease experimental models (Bartlett
et al., 2014). However, similar evidence from human studies
is lacking. Measurement of serum IL-1 in autoimmune and
autoinflammatory diseases is seldom significantly elevated, and
is not thought to be a reliable indicator of inflammation
(Dinarello, 2005). Therefore, it is not possible to verify in
humans whether P2X7R blockade has any effect on IL-1β
release. Assessing the in vivo effect of P2X7R blockade on IL-
1, and in general, all cytokines, release, is made even more
complex by the disappointing results of most clinical trials so
far carried out (De Marchi et al., 2016; Jacobson and Muller,
2016).
CONCLUSION
Extracellular ATP is now acknowledged to be one of the
earliest most ubiquitous DAMPs (Di Virgilio, 2013; Kepp
et al., 2014; Hammad and Lambrecht, 2015; Venereau et al.,
2015). Its remarkable efficiency and plasticity as an alarm
signal strongly depends on the diverse of ATP-selective
plasma membrane receptors expressed by immune cells. Very
interestingly, even before all ATP receptors (P2 receptors)
expressed by immune cells were cloned and fully characterized,
it was clear that stimulation with extracellular ATP was able
to cause a dramatic acceleration of pro-IL-1β processing and
release from monocytes/macrophages, as well as from microglial
cells, and this was very likely a receptor-mediated event
(Perregaux and Gabel, 1994; Di Virgilio et al., 1996; Ferrari
et al., 1996). About at the same time the P2X7R was cloned
(Surprenant et al., 1996), and soon after identified as the
molecule responsible for ATP-dependent mature IL-1β release
(Ferrari et al., 1997). Thus, the association between IL-1β
and the P2X7R is rock solid and long standing. However,
this has not led to the introduction of any P2X7R-targeted
anti-inflammatory therapy, despite large effort by virtually
all major Pharma Industries. Are we missing some crucial
information of P2X7R and IL-1β biology, or is there a recurrent
fault in P2X7R-targeting drug design and development, or
both?
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